http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9968625-B2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_041830b7e15173f775e57492a54f67ff |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-702 |
filingDate | 2015-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2018-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7e74f9d27461f1345f0e41d6e651046 |
publicationDate | 2018-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-9968625-B2 |
titleOfInvention | Synthetic or recombinant fucosylated oligosaccarides for use in the treatment of infections |
abstract | The present invention relates to synthetic fucosylated oligosaccharide for use in the treatment or prophylaxis of an infection with a Norwalk-like Virus or Rotavirus of a mam-mal, wherein the synthetic fucosylated oligosaccharide comprises a non-reducing end and an reducing end, wherein the reducing end comprises a first carbohydrate unit consisting of a galactose (Gal) linked via a β1-4 glycosidic bond to a glucose (Glc), and wherein the non-reducing end comprises a second carbohydrate unit linked via a β1-3 glycosidic bond to the first carbohydrate unit of the reducing end, and wherein the second carbohydrate unit comprises a) at least one or more of a fucose (Fucose) and a Galactose (Gal), and b) at least one or more of a N-acetylglucosamine (GlcNAc) or a N-acetylgalactosamine (GalNAc). |
priorityDate | 2013-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.